ISSN 1004-6879

CN 13-1154/R

 
  Journals
  Publication Years
  Keywords
Search within results Open Search
Please wait a minute...
For Selected: Toggle Thumbnails
Effect of hsa-circ-0001862 on the Phenotype of Tongue Squamous Cell
LIU Xue, XIONG Hui, SU Yong-zhi, WANG Yang-Yang, WANG Peng, TAO Ya-dong
Abstract23)      PDF (7409KB)(3)      
Objective To investigate the effect of circular RNA hsa-circ-0001862 on the phenotype of tongue squamous cell carcinoma and its mechanism on the occurrence and development of tongue squamous cell carcinoma. Methods hsa-circ-0001862 plasmid was constructed, and the interaction relationship between hsa-circ-0001862 and miR-23a-3p was verified by double luciferase reporter gene and qRT-PCR. After targeted inhibition of hsa-circ-0001862, CCK8 assay and colony formation assay were used to detect the cell viability and colony formation ability of tongue squamous cell carcinoma cells. The migration and invasion ability of tongue squamous cell carcinoma cells were detected by scratch test and Transwell test. Apoptosis-related proteins were detected by Western blot to reflect the effect of hsa-circ-0001862 on the apoptosis of tongue squamous cell carcinoma cells. Results hsa-circ-0001862 and miR-23a-3p could interact, and their expression was negatively correlated in tongue squamous cell, carcinoma cells. In Tca-8113 cells, hsa-circ-0001862 inhibited cell proliferation, migration and invasion (P<0.01), and promoted cell apoptosis (P<0.01). Conclusion hsa-circ-0001862 interacts with miR-23a-3p, and hsa-circ-0001862 plays an inhibitory role in the development of tongue squamous cell carcinoma. hsa-circ-0001862 may be a new biomarker and target for the treatment of tongue squamous cell carcinoma.
2024, 41 (3): 185-189.
Expression and Prognostic Value of miR-125b-5p in Lung Adenocarcinoma Based on Bioinformatics Analysis
GUO Na, XU Ying, LI Xiang-ling, WANG Peng, LI Lin, XU Qian, LIU Lei
Abstract144)      PDF (2236KB)(35)      
Objective To analyze the expression of miR-125b-5p in lung adenocarcinoma (LUAD), and predict its target genes and prognostic value by bioinformatics analysis. Methods Tissue and cell chips of cisplatin resistance-related LUAD in Gene Expression Omnibus (GEO) database were obtained, and differentially expressed miRNAs were screened by R software. The miRBase database was used to analyze conservativeness, and the dbDEMC3.0 database was used to evaluate the expression level. The target genes were predicted by TargetScan, miRDB and miRTarBase databases, and were analyzed for functional term enrichment with the DAVID database. Combined with the survival information of LUAD patients in the Cancer Genome Atlas (TCGA) database, prognostic analysis was performed. Quantitative Real-time PCR (qRT-PCR) detection technology was used to detect the expression level of miR-125b-5p in human normal bronchial epithelial cell line 16HBE, LUAD cell line A549, and cisplatin-resistance cell line A549/DDP. Results miR-125b-5p, closely related to cisplatin resistant of LUAD, was obtained by analysis of the chip data. The sequence of miR-125b-5p was highly conserved among species, and miR-125b-5p was significantly down-regulated in various tumors including LUAD. Fifty-four target genes of miR-125b-5p were predicted. The results of enrichment analysis showed that the target genes of miR-125b-5p were mainly involved in the regulation of gene expression, cellular macromolecule biosynthetic process, and mainly enriched on MicroRNAs in cancer, Protein processing in endoplasmic reticulum, and HIF-1 signaling pathway. Survival analysis indicated that miR-125b-5p was significantly associated with poor prognosis of patients with LUAD. qRT-PCR results showed that the expression level of miR-125b-5p in A549 was significantly lower than in 16HBE (P=0.008). Compared to parental cell, the expression level of miR-125b-5p was significantly down-regulated in A549/DDP cell (P=0.023). Conclusion miR-125b-5p was abnormally expressed in LUAD, and its target genes involved in multiple biological processes and signal pathways, which might be used as a new biomarker for prognosis in LUAD.
2022, 39 (5): 365-370.